Torrent Pharma July-September Profit Surges 30.5% On Year; Revenue up 14.3%

Torrent Pharmaceuticals Ltd. reported strong financial performance for the September quarter, with both profit and revenue rising sharply on year, supported by growth across key geographies and therapeutic segments.

The company’s consolidated net profit jumped 30.5% on year to ₹5.9 billion in July–September, marking its strongest quarterly growth in six quarters. Consolidated revenue rose 14.3% on year to a little over ₹33 billion, led by its India, US, and Brazil operations.

Total expenditure for the quarter grew 11.7% on year to ₹24.7 billion as raw material and employee costs climbed. Employee expenses, which account for around a fourth of total costs, rose 15.5% on year to ₹6.3 billion, while raw material costs increased 13.4% to ₹3.8 billion. Purchase of stock-in-trade remained stable at ₹3.8 billion, and finance costs fell 25% to ₹480 million, providing some cushion to overall expenses.

Operating earnings before interest, tax, depreciation, and amortisation rose 15.3% on year to ₹10.8 billion, with an EBITDA margin of 32.8%. Research and development expenditure stood at ₹1.6 billion, up 7.6% on year.

For April–September, consolidated net profit grew 25.2% on year to ₹11.4 billion, while revenue increased nearly 13% to ₹64.8 billion. Operating EBITDA for the first half rose 14.8% to ₹21.2 billion.

India, which contributes about 55% of Torrent Pharma’s revenue, recorded a 12% on-year growth to ₹18.2 billion, driven by its focus therapies. The company’s chronic business grew 13%, outpacing the overall industry growth of 11%. Torrent Pharma said its new product launches continued to perform well, with 21 of its brands among the top 500 in India and 15 brands generating sales exceeding ₹1 billion each.

In the US, the company’s largest market outside India, revenue increased 26% on year to ₹3.4 billion, or 21% in constant currency terms. Recent product launches achieved their targeted market shares, the company said.

Revenue from Brazil rose 21% on year to ₹3.2 billion, supported by strong brand performance and new launches. Torrent Pharma currently has 65 products under review with Brazil’s Health Surveillance Agency, Anvisa.

In Germany, revenue rose 5% on year to ₹3 billion, although in constant currency terms it declined 5% to €30 million due to a supply disruption at a third-party vendor’s facility.